Several COVID-19 vaccine candidates are poised to hit the market in the coming weeks and months, promising some salvation from the horrific and lengthy pandemic of 2020.
The world has been dealing with this novel strain of coronavirus for nearly a year now, after the illness spread from bats to humans at a “wet market” in Wuhan, China back in December of 2019. As it spread to Europe, and as China deceived the rest of the world as to the severity of the sickness, COVID-19 began to ravage the globe.
Now, as salvation looks to arrive in the form of a jab in the arm, one of the earliest vaccines to hit the market is now coming with a warning about some potentially fatal side effects.
Two people who were jabbed with Pfizer’s recently-approved coronavirus vaccine in the UK had to be treated for serious adverse reactions — leading to warnings that those with “significant” allergies may not be able to get it.
The unidentified duo — both staff in the UK’s National Health Service (NHS) — needed treatment for an “anaphylactoid reaction” Tuesday after they were among the first in the world to get the shot.
They both had serious reactions, but recovered after treatment, the NHS said.
The pair both had a history of allergic responses, and each carried an adrenaline shot — sometimes called EpiPens — used to save people from potentially fatal reactions.
And while the introduction of a vaccine seems like a sure fire way to end the pandemic, being forced to exclude certain segments of the population on account of these potentially life-threatening side effects could make it difficult to inoculate enough human beings to bring about the necessary immunity to the virus.